上海医药B023细胞注射液临床试验获批

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its self-developed "B023 cell injection" for treating locally advanced or metastatic solid tumors that are inoperable and have no effective treatment options after standard therapy failure [1] Group 1 - The "B023 cell injection" is aimed at patients with locally advanced or metastatic solid tumors [1] - The approval allows the company to conduct clinical trials for a treatment that currently lacks effective options [1] - This development highlights the company's commitment to advancing innovative therapies in oncology [1]